MedTrace Logo

Lipid Efficacy/Tolerability Study (0524A-020)

NCT00269204 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1620

Last updated 2015-07-27

No results posted yet for this study

Summary

A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups. A patient can be randomly assigned to 1 of the 3 treatment groups.

Conditions

  • Primary Hypercholesterolaemia
  • Mixed Hyperlipidaemia

Interventions

DRUG

niacin (+) laropiprant

Duration of Treatment - 24 weeks

DRUG

ER-niacin

Duration of Treatment - 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2006-12-31
Completion
2006-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00269204 on ClinicalTrials.gov